|Bid||6.51 x 1800|
|Ask||6.52 x 3100|
|Day's Range||6.46 - 6.78|
|52 Week Range||3.26 - 8.36|
|Beta (5Y Monthly)||2.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.71|
By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update Management Provides Update on 2021 Outlook We recently spoke to the management team at Viking Therapeutics, Inc. (NASDAQ:VKTX), including CEO Brian Lian, regarding the outlook for the company in 2021 and anticipated milestones regarding the ongoing Phase 2b clinical trial of VK2809 in non-alcoholic steatohepatitis
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced two key executive promotions. The company has named Greg Zante as chief financial officer and Marianne Mancini as chief operating officer.
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2021 Conference. The conference, which will take place January 11-14, 2021, is being conducted with a virtual format.